Communiqués Matricelf Ltd OTC Markets

Actions

Marché Fermé - OTC Markets Autres places de cotation 20:27:58 25/08/2022			Varia. 5j.	Varia. 1 janv.
1,900 ^USD	-40,99%		-.--%	-

09/07	Matricelf Ltd. reçoit l'autorisation de débuter l'identification des patients et les prélèvements sanguins pour sa première étude clinique sur les lésions de la moelle épinière	CI
22/06	Matricelf lance une étude d'efficacité pré-IND pour son implant de tissu neural humain destiné aux lésions chroniques de la moelle épinière	CI

09/07	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR
26/02	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation	PR
21/08/25	Tel Aviv University: Israeli Breakthrough: First Human Trial of Engineered Spinal Cord	AQ
12/03/25	Cellino and Matricelf, New Hope for Spinal Cord Injuries	AQ
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	BU
27/03/24	Matricelf : INVESTORS PRESENTATION	PU